Is LEGN or LIXT more undervalued in 2026?

CirclFi compares Legend Biotech Corporation (LEGN) and Lixte Biotechnology Holdings, I (LIXT) using 13 institutional-grade valuation models. LEGN has a Quality of Company score of 1.7/10 while LIXT scores 4.2/10.

Which is a better buy — LEGN or LIXT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do LEGN and LIXT valuations compare?

LEGN at $28.26 and LIXT at $5.99 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

LEGN vs LIXT Valuation Comparison 2026 — Intrinsic Value Analysis

LEGN

Biotechnology

Legend Biotech Corporation

Quality

1.7

out of 10

Value Trap

—

Price

$28.26

Last close

Models

12/13

Active

LIXT

Biotechnology

Lixte Biotechnology Holdings, I

Quality

4.2

out of 10

Value Trap

SAFE

Price

$5.99

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	LEGN Fair Value	LEGN Upside	LIXT Fair Value	LIXT Upside
Bayesian DCF	Intrinsic	$8.34	-70.5%	$1.66	-72.3%
Earnings Power Value	Intrinsic	$10.13	-57.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.71	-90.5%	$0.71	-88.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for LEGN vs LIXT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LEGN vs LIXT — Which Stock Is More Undervalued?

LIXT scores higher with a 4.2/10 quality rating vs LEGN's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Legend Biotech Corporation (LEGN) and Lixte Biotechnology Holdings, I (LIXT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LEGN currently trades at $28.26 with a QOC of 1.7/10, while LIXT trades at $5.99 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).